172@29@17@144!~!172@29@0@53!~!|news|tags|sun-pharma.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
you are here: HomeNewsSun pharma
sun pharma
Jump to
1202 Results Found
  • Trade Spotlight: ICICI Bank, Sun Pharma, and Future Retail in focus Sep 01, 2020 08:21 AM IST

    Trade Spotlight: ICICI Bank, Sun Pharma, and Future Retail in focus

    ICICI Bank fell more than 3 percent, Sun Pharma plunged more than 6 percent, and Future Retail was up 20 percent.

  • Sun Pharma arm resolves product promotion investigation with US justice dept Aug 25, 2020 12:55 PM IST

    Sun Pharma arm resolves product promotion investigation with US justice dept

    "DUSA fully cooperated with DOJ in its investigation of a complaint filed by a former employee in September 2016,” Sun Pharmaceutical Industries said in a regulatory filing.

  • Buy Sun Pharma; target of Rs 619 KRChoksey Aug 09, 2020 09:02 AM IST

    Buy Sun Pharma; target of Rs 619 KRChoksey

    KRChoksey is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 619 in its research report dated August 07, 2020.

  • Hold Sun Pharma; target of Rs 542: Emkay Global Financial Aug 08, 2020 02:42 PM IST

    Hold Sun Pharma; target of Rs 542: Emkay Global Financial

    Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 542 in its research report dated July 31, 2020.

  • Buy Sun Pharma; target of Rs 625: Motilal Oswal Aug 07, 2020 01:42 PM IST

    Buy Sun Pharma; target of Rs 625: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 625 in its research report dated August 01, 2020.

  • Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22 Aug 03, 2020 09:47 AM IST

    Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

    What adds to the Sun Pharma's investment case is the prospect for US specialty. The management hopes to achieve EBITDA break-even for a few products next fiscal

  • Sun Pharma Consolidated June 2020 Net Sales at Rs 7,585.25 crore, down 9.42% Y-o-Y Aug 03, 2020 09:25 AM IST

    Sun Pharma Consolidated June 2020 Net Sales at Rs 7,585.25 crore, down 9.42% Y-o-Y

  • Sun Pharma Standalone June 2020 Net Sales at Rs 2,963.04 crore, down 10.46% Y-o-Y Aug 03, 2020 09:22 AM IST

    Sun Pharma Standalone June 2020 Net Sales at Rs 2,963.04 crore, down 10.46% Y-o-Y

  • Sun Pharma Q1 likely to be muted due to high base effect, weak domestic business Jul 31, 2020 11:20 AM IST

    Sun Pharma Q1 likely to be muted due to high base effect, weak domestic business

    Global brokerage firm Phillip Capital expects Sun Pharma's sales to remain muted due to the high base of last year and underperformance in domestic business because of COVID.

  • Sun Pharma gets nod from Japan govt for plaque psoriasis treatment drug Jun 29, 2020 02:30 PM IST

    Sun Pharma gets nod from Japan govt for plaque psoriasis treatment drug

    The wholly-owned subsidiary has received approval from Japan's Ministry of Health, Labour and Welfare for Ilumya (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies, Sun Pharmaceutical Industries said in filing to BSE.

  • Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA region Jun 15, 2020 01:32 PM IST

    Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA region

    One of the company's wholly-owned subsidiaries and Hikma Pharmaceuticals have entered into the agreement for Ilumya, Sun Pharma said in a filing to BSE.

  • Sun Pharma share price jumps 3% as CLSA maintains buy Jun 09, 2020 10:30 AM IST

    Sun Pharma share price jumps 3% as CLSA maintains buy

    CLSA is of the view that Sun Pharma's EBITDA contribution of specialty is likely to rise to 15 percent from nil by FY22 while specialty business in US comprising of nine products is at an inflexion point.

  • Buy Sun Pharma ; target of Rs 525: Motilal Oswal May 28, 2020 04:29 PM IST

    Buy Sun Pharma ; target of Rs 525: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 525 in its research report dated May 27, 2020.

  • The wait for Sun Pharma to rise gets longer May 28, 2020 11:09 AM IST

    The wait for Sun Pharma to rise gets longer

  • Sun Pharma Standalone March 2020 Net Sales at Rs 2,836.08 crore, up 11.13% Y-o-Y May 28, 2020 09:40 AM IST

    Sun Pharma Standalone March 2020 Net Sales at Rs 2,836.08 crore, up 11.13% Y-o-Y

  • Sun Pharma Consolidated March 2020 Net Sales at Rs 8,184.94 crore, up 14.25% Y-o-Y May 28, 2020 09:25 AM IST

    Sun Pharma Consolidated March 2020 Net Sales at Rs 8,184.94 crore, up 14.25% Y-o-Y

  • Coronavirus pandemic opens up a huge opportunity for Indian pharma Apr 14, 2020 08:53 AM IST

    Coronavirus pandemic opens up a huge opportunity for Indian pharma

    Local drug companies should address some of the longer term issues concerning the industry such as quality and good manufacturing practices

  • Coronavirus pandemic | Sun Pharma commits Rs 25 cr worth of drugs, sanitisers to fight COVID-19 Mar 28, 2020 06:27 PM IST

    Coronavirus pandemic | Sun Pharma commits Rs 25 cr worth of drugs, sanitisers to fight COVID-19

    "The company is committed to working closely with the governments and relevant stakeholders to ensure that there is uninterrupted supply of medicines," Sun Pharma said in a statement.

  • Sun Pharma board approves Rs 1,700cr share buy-back offer Mar 17, 2020 02:46 PM IST

    Sun Pharma board approves Rs 1,700cr share buy-back offer

    In a regulatory filing the company said that the board of directors of the company, at its meeting held on Tuesday has approved the buy-back of its equity shares from the open market at a maximum price of Rs 425 per share for an aggregate maximum amount of up to Rs 1,700 crore.

  • Sun Pharma share price up 3% after Morgan Stanley remains overweight Mar 03, 2020 11:15 AM IST

    Sun Pharma share price up 3% after Morgan Stanley remains overweight

    The stock was trading with volumes of 654,539 shares, compared to its five-day average of 422,811 shares, an increase of 54.81 percent.

  • Sun Pharma Consolidated December 2019 Net Sales at Rs 8,154.85 crore, up 5.36% Y-o-Y Feb 07, 2020 11:45 AM IST

    Sun Pharma Consolidated December 2019 Net Sales at Rs 8,154.85 crore, up 5.36% Y-o-Y

  • Sun Pharma share price gains despite drop in Q3 profit; Morgan Stanley, CLSA retain buy Feb 07, 2020 10:50 AM IST

    Sun Pharma share price gains despite drop in Q3 profit; Morgan Stanley, CLSA retain buy

    The company declared an interim dividend of Rs 3 per share for FY20

  • Market Headstart: Nifty50 seen opening flat; Balrampur Chini, L&T top buys Dec 16, 2019 08:12 AM IST

    Market Headstart: Nifty50 seen opening flat; Balrampur Chini, L&T top buys

    Trends on SGX Nifty indicate a flat opening for the broader index in India, with a 5-point loss or 0.04 percent

  • Sun Pharma slips 2% after Q2 results; Citi, CLSA maintain buy - Here's why Nov 08, 2019 10:36 AM IST

    Sun Pharma slips 2% after Q2 results; Citi, CLSA maintain buy - Here's why

    Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 16.9 percent to Rs 1,790 crore in Q2FY20, while margin remained flat at 22 percent YoY.

  • Sun Pharma inks licensing pact with AstraZeneca to introduce products in China Nov 06, 2019 10:00 AM IST

    Sun Pharma inks licensing pact with AstraZeneca to introduce products in China

    This comes after AstraZeneca said it was launching a new fund with China International Capital Corp to invest $1 billion in China's healthcare sector, as it expands its research work in the country.

Sections